The position the Company aspires to establish by FY2033 is to become a company that strongly turns the “value creation cycle” and continuously translates innovation into real-world solutions focusing on disease fields in oncology, psychiatry & neurology and others, and on modalities such as small molecules and regenerative medicine/cell therapy. By turning the value creation cycle, the Company will strategically deepen and expand these strengths as well as establish a distinctive global presence in order to contribute to the betterment of healthcare and fuller lives of people worldwide.



Important Notice
Showcase Sumitomo Pharma in a nutshell
Here you can search for the strengths of Sumitomo Pharma’s business, Sumitomo Pharma’s initiatives, and other information that interests you by selecting tags.
Strengths Sumitomo Pharma’s Three Strengths
- 1R&D Capabilities
- 2Human Resources
- 3Global Business Platforms
Press Releases
- Aug. 05, 2025 Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan R&D
- Aug. 05, 2025 Notice Regarding the Completion of the CRAFT Regenerative Medicine and Cell Therapy Manufacturing Facility Corporate
- Aug. 04, 2025 Sumitomo Pharma Announces Organizational Realignments and Personnel Changes Corporate
- Aug. 01, 2025 Sumitomo Pharma's Novel TLR7 Vaccine Adjuvant Selected for the CEPI Adjuvant Library -Innovative Technology that could contribute to Pandemic Preparedness- R&D
- Jul. 31, 2025 Presentation Material (Conference on Q1 FY2025 Financial Results)(PDF/925KB) Finances
Notices
- Jun. 30, 2025 Consolidated Financial Statements for Years ended March 31, 2025 and 2024 Finances
- May 30, 2025 Posted Notice of Convocation of the 205th Annual Shareholders' Meeting Corporate
- May 27, 2025 Caution Regarding Suspicious Emails Impersonating the Company Others
For the Press
Our latest press releases and other information for members of the press,
including various data sets and guidelines for their use.
-
Sustainability
Sumitomo Pharma defines the practice of its Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as Sustainability Management. To this end , Sumitomo Pharma is pursuing Sustainability Management through a variety of initiatives, including the development of innovative products and healthcare solutions, and contribution to the development of science.
-
About Us
Message from the President, corporate profile of Sumitomo Pharma, business activities, mid-term management plan, key locations and group companies, etc.
-
Investor Relations
Information for shareholders and investors of Sumitomo Pharma, including management policies, IR materials, and stock and shareholder-related information.